So, to further evaluate the therapeutic efficacy of our anti-TDP-43 antibody in ALS–CSF–induced pathology in the brain, we decided to test the effects of E6 antibody when co-infused i.c.v. with ALS-CSF in the hTDP-43WT mice. The gene discussed is CSF2; the disease is amyotrophic lateral sclerosis.